Att%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520drugs

**Drug:** Atorvastatin ## Overview Atorvastatin is a statin medication used to lower cholesterol levels in the blood. It works by inhibiting HMG-CoA reductase, a key enzyme in cholesterol synthesis. ## Primary Indications * Hyperlipidemia (primary prevention and treatment) * Prevention of cardiovascular events in patients with risk factors for heart disease. ## Adult Dosing * **Hyperlipidemia:** Start with 10-20 mg once daily. Titrate dose as needed based on lipid response. Maximum dose is 80 mg once daily. * **Cardiovascular Event Prevention:** 10-80 mg once daily. ## Pediatric Dosing * **Age 10-17 years (Heterozygous Familial Hypercholesterolemia):** 10 mg once daily. Titrate to 20 mg once daily if needed. Maximum dose is 40 mg once daily. Dosing in younger children is not established. ## Dose Adjustments * **Renal Impairment:** No dose adjustment is typically required. * **Hepatic Impairment:** Use with caution. In patients with moderate hepatic impairment, consider a lower starting and maintenance dose. Avoid in patients with active liver disease. ## Contraindications * Active liver disease or unexplained persistent elevations of serum transaminases. * Hypersensitivity to atorvastatin or any component of the formulation. * Pregnancy and breastfeeding. ## Adverse Effects * **Common:** Myalgia, diarrhea, nausea, arthralgia, nasopharyngitis. * **Serious:** Rhabdomyolysis, hepatotoxicity, hyperglycemia, cognitive impairment. ## Key Drug Interactions * **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, protease inhibitors, erythromycin, clarithromycin, grapefruit juice):** Increase atorvastatin concentration, increasing the risk of myopathy and rhabdomyolysis. * **CYP3A4 Inducers (e.g., rifampin, efavirenz):** May decrease atorvastatin concentration. * **Fibrates and other lipid-lowering agents (e.g., gemfibrozil, fenofibrate):** Increased risk of myopathy and rhabdomyolysis. * **Colchicine:** Increased risk of myopathy and rhabdomyolysis. * **Warfarin:** May increase INR. Monitor INR closely when initiating or adjusting atorvastatin. ## Monitoring * **Baseline:** Liver function tests (ALT, AST), lipid panel. * **Routine:** Liver function tests periodically (e.g., 6-12 weeks after initiation or dose change, then as clinically indicated). Monitor for signs and symptoms of myopathy (muscle pain, tenderness, weakness). * **Consider:** Creatine kinase (CK) if myopathy is suspected. ## Clinical Pearls * Atorvastatin is typically taken once daily, with or without food. * The maximum dose of 80 mg daily should be reserved for patients who have not achieved their LDL-C goal on lower doses and for whom the benefits are expected to outweigh the increased risk of adverse events. * Advise patients to report any unexplained muscle pain, tenderness, or weakness, especially if accompanied by malaise or fever. * Educate patients to avoid excessive consumption of grapefruit juice, as it can increase atorvastatin levels. *** *Disclaimer: This information is intended for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional and refer to the most current prescribing information before making any decisions related to patient care.*